Skip to main content

Advertisement

Table 2 Prognostic markers involved in regulating proliferation in ESCC as reported in original studies

From: Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review

Marker References Sample size Clinical stage OS DFS Analytic methods
HR 95% CI P value HR 95% CI P value
EGFR Zhang et al. [10] 441 IB-IIIC 1.452 1.137–1.855 0.003 1.351 1.057–1.728 0.016 Cox proportional hazards model
Zhang et al. [19] 128 II–IV >0.05 Log-rank test
Cao et al. [29] 315 I–IV 1.614 1.027–2.536 0.038 Cox proportional hazards model (univariate)
Shang et al. [30] 590 I-III 2.652 1.708-4.118 0.00001 Cox proportional hazards model
Jiang et al. [31] 96 0.007 0.006 Log-rank test
Xu et al. [32] 87 I–III 1.728 1.011–2.955 0.046 Cox proportional hazards model
HER2 Zhang et al. [19] 128 II–IV >0.05 Log-rank test
Mimura et al. [33] 66 0–IV 0.92 0.35–2.41 0.861 Cox proportional hazards model,
Sunpaweravong et al. [34] 55 II–IV 0.04 Log-rank test
Zhan et al. [35] 145 I–IV 0.036 Log-rank test
p-mTOR Hirashima et al. [36] 143 I–III 2.92 1.48–5.78 0.002 Cox proportional hazards model
Kim et al. [37] 165 I–IV 1.47 0.92-2.35 0.104 1.67 1.07–2.62 0.025 Cox proportional hazards model
Li et al. [38] 105 I–IV 0.022 0.014 Log-rank test
Li et al. [39] 77 II–III 2.814 1.553–5.097 0.001 2.438 1.368–4.347 0.003 Cox proportional hazards model
P16 Mathew et al. [11] 50 I–IV >0.05 Log-rank test
Okamoto et al. [20] 86 I–IV 0.19 0.14 Cox proportional hazards model (univariate)
Cao et al. [42] 105 I–III 4.23 1.75–8.54 0.03 2.52 1.12–5.71 0.02 Cox proportional hazards model
Guan et al. [43] 90 I–IV 0.234 0.086–0.637 0.004 Cox proportional hazards model
Takeuchi et al. [44] 90 I–III 0.312 0.003 Cox proportional hazards model
Guner et al. [45] 53 I–III 0.410 0.203–0.828 0.013 Cox proportional hazards model (univariate)
Fujiwara et al. [46] 60 I–IV 0.597 0.287–1.032 0.067 Cox proportional hazards model
P21 Shiozaki et al. [12] 69 I–IV 0.381 0.123–0.995 0.049 Cox proportional hazards model
  1. ESCC esophageal squamous cell carcinoma, EGFR epidermal growth factor receptor, HER2 human epidermal growth factor receptor-2, p-mTOR phosphorylated mammalian target of rapamycin, OS overall survival, DFS disease-free survival, HR hazard ratio, CI confidence interval, no data